Cytokinetics, Inc. (CYTK) Posts Q2 Loss of 23c/Share
Tweet
Share
E-mailGet Alerts CYTK Hot Sheet
Price: $70.15 +1.27%
Revenue Growth %: -75.3%
Financial Fact:
Research and development, grant and other revenues: 441K
Today's EPS Names:
PLCE, COE, JVA, More
Revenue Growth %: -75.3%
Financial Fact:
Research and development, grant and other revenues: 441K
Today's EPS Names:
PLCE, COE, JVA, More
Join SI Premium – FREE
Cytokinetics, Inc. (NASDAQ: CYTK) reported Q2 EPS of ($0.23), $0.09 better than the analyst estimate of ($0.32). Revenue for the quarter came in at $7.8 million versus the consensus estimate of $7.01 million.
For earnings history and earnings-related data on Cytokinetics, Inc. (CYTK) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Nvidia pitches Vera CPU to Chinese clients with August delivery target
- UBS Reiterates Neutral Rating on Lennar (LEN) Following Q2 Results
- Sharon AI secures six-year compute deal with NVIDIA for Australia deployment
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
